Files and links (1)
CC BY V4.0, Open Access
Journal article
Horse owner experiences and observations with the use of SGLT2i for the management of equine metabolic syndrome and hyperinsulinaemia-associated laminitis
Equine veterinary education, Vol.37(4), pp.202-209
2024
Appears in Open Access via Read & Publish Agreements
Abstract
Background
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are being used increasingly in equine practice. While there is emerging clinical evidence of the safety and efficacy of these drugs, there are currently no reports to document owner experiences with treatment.
Objective
The objective of the study was to report owner experiences and observations following treatment with SGLT2i in horses.
Study design
A cross-sectional online survey.
Methods
Horse owners were recruited via social media, online forums and their veterinarians to participate in an anonymous online survey to document their experiences and observations when treating their horses with SGLT2i.
Results
Three hundred forty-two responses met the inclusion criteria. Ertugliflozin was the most commonly prescribed SGLT2i (79.8%), and the most common reasons for treatment were high insulin concentrations (84.2%) and active laminitis (59.7%). 85.3% of owners reported their horses had an improved quality of life after commencing treatment, while 9.4% reported no change and 5.3% reported a worsening of clinical signs. Of owners who had considered euthanasia prior to treatment (n = 77), 80.5% reported their horse's level of pain to be either mild or absent after 30 days of treatment and 94.8% reported their horse's quality of life to be improved. Most owners (n = 220, 64.7%) reported they were either extremely satisfied or somewhat satisfied (n = 72, 21.2%) with treatment. Treatment concerns included safety/side effects, medication cost, availability and long-term efficacy. 114 owners (33.3%) reported one or more initial adverse effects upon induction onto the medication, particularly excessive urination (n = 70, 20.5%), excessive drinking (n = 38, 11.1%), excessive weight loss (n = 34, 9.9%) and dullness (n = 26, 7.6%).
Main limitation
Sampling bias through social media and veterinary practices and reliance on subjective owner reports.
Conclusion
The use of SGLT2i in horses was associated with excellent rates of owner satisfaction and owner-reported improved quality of life for the horse; however, some adverse effects were observed.
Details
- Title
- Horse owner experiences and observations with the use of SGLT2i for the management of equine metabolic syndrome and hyperinsulinaemia-associated laminitis
- Authors/Creators
- Tania Sundra - Avon (United States)Erin Kelty - The University of Western AustraliaGabriele Rossi - Murdoch University, Centre for Animal Production and HealthGuy Lester - Equiimed, Perth, WA, AustraliaDavid Rendle - EMT Consulting, Tiverton, England
- Publication Details
- Equine veterinary education, Vol.37(4), pp.202-209
- Publisher
- John Wiley & Sons Ltd on behalf of EVJ Ltd.
- Number of pages
- 8
- Identifiers
- 991005656565407891
- Copyright
- © 2024 The Authors.
- Murdoch Affiliation
- School of Veterinary Medicine; Centre for Animal Production and Health
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Metrics
43 File views/ downloads
167 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Citation topics
- 3 Agriculture, Environment & Ecology
- 3.232 Veterinary Sciences
- 3.232.1304 Equine Orthopedics
- Web Of Science research areas
- Veterinary Sciences
- ESI research areas
- Plant & Animal Science